Johnson & Johnson $JNJ Stock: Boomfish Wealth Group LLC Cuts Stake

Key Points

• Boomfish Wealth Group LLC cut its Johnson & Johnson stake by 63.3% in the third quarter, selling 5,725 shares and retaining 3,322 shares valued at approximately $879,000. Institutional investors collectively own 69.55% of J&J.
• J&J reported quarterly EPS of $2.59, beating estimates by $0.06, while revenue rose 5.9% year over year to $25.40 billion. The company provided fiscal 2026 EPS guidance of $11.05–$11.15.
• The company declared a quarterly dividend of $1.34 per share, equivalent to a $5.36 annualized payout and a 2.0% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $275.92.

Boomfish Wealth Group LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 63.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,322 shares of the company's stock after selling 5,725 shares during the period. Boomfish Wealth Group LLC's holdings in Johnson & Johnson were worth $879,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. National Pension Service grew its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company's stock worth $1,327,493,000 after buying an additional 67,484 shares during the period. IFP Advisors Inc boosted its position in shares of Johnson & Johnson by 8.8% in the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after purchasing an additional 3,133 shares during the last quarter. Elefante Mark B grew its stake in shares of Johnson & Johnson by 9.8% during the second quarter. Elefante Mark B now owns 28,686 shares of the company's stock worth $7,285,000 after purchasing an additional 2,563 shares during the period. Gradient Investments LLC grew its stake in shares of Johnson & Johnson by 9.9% during the second quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock worth $38,815,000 after purchasing an additional 13,737 shares during the period. Finally, Louisiana State Employees Retirement System bought a new stake in Johnson & Johnson in the first quarter valued at about $30,017,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ opened at $264.13 on Monday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07. The company has a fifty day simple moving average of $265.64 and a 200 day simple moving average of $250.28. The stock has a market cap of $635.85 billion, a P/E ratio of 40.02, a P/E/G ratio of 2.61 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm's revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is 81.21%.

Insider Transactions at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 64,515 shares of company stock valued at $17,271,766 over the last 90 days. 0.16% of the stock is owned by company insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J's oral psoriasis pill
• Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data
• Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers
• Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment
• Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed
• Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on JNJ shares. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 16th. Wall Street Zen lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. Guggenheim reaffirmed a "buy" rating and issued a $287.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 7th. Finally, JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $275.92.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.